Early Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma (MM) based on specific medical criteria, such as abnormal protein levels in the blood or urine, or abnormal plasma cell counts in the bone marrow (confirm with trial site for exact diagnostic details)
• People whose multiple myeloma is currently measurable through blood or urine tests showing abnormal protein levels above certain thresholds
• People whose multiple myeloma has come back or stopped responding to treatment, and who have already received at least two prior treatment regimens that included lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody drug
• People who have never previously been treated with a drug called ruxolitinib
• People who are willing and able to sign a consent form agreeing to take part, understanding they may withdraw at any time
• People who are able to follow the study schedule and meet all the study requirements
• People whose general physical health is rated at a level of 0, 1, or 2 on a standard medical activity scale (meaning they are able to carry out some or all daily activities, confirm with trial site)
• People whose life expectancy is greater than 3 months
• People whose blood test results fall within specific ranges at the screening stage, including adequate white blood cell, platelet, and red blood cell counts, acceptable kidney function, liver enzyme levels within normal limits, and normal potassium levels (confirm with trial site for exact values)
• People joining Part 2 of the study who are willing and able to comply with a mandatory safety program associated with lenalidomide use
• Women who could become pregnant must have a negative pregnancy test before starting treatment and must agree to use two forms of contraception at the same time, starting at least 28 days before treatment, and continue pregnancy testing throughout the study; men must agree to use a condom during sexual contact with a woman who could become pregnant, even if they have had a vasectomy
• People who are able to take antiplatelet therapy (such as low-dose aspirin or an alternative if aspirin is not tolerated) if their platelet count is above a certain level

Who may not be able to join:

• People diagnosed with POEMS syndrome (a rare condition involving nerve damage, organ enlargement, hormone problems, abnormal proteins, and skin changes)
• People with plasma cell leukemia, where a high number of abnormal plasma cells are circulating in the blood
• People with primary amyloidosis (a condition where abnormal proteins build up in organs)
• People who have had a non-blood cancer in the past 5 years, with some exceptions for certain low-risk or fully treated cancers such as certain skin cancers, early-stage cervical or breast changes, low-grade prostate cancer, or cancers considered cured by surgery (confirm with trial site for specific exceptions)
• People with infections that are not currently under control
• People with significant heart problems, including a heart attack in the last 6 months, moderate-to-severe heart failure, uncontrolled chest pain, serious heart rhythm problems, severely high blood calcium levels, or certain abnormal heart test results (confirm with trial site for full details)
• People with a serious medical condition, significant abnormal lab results, or a mental health condition that would prevent them from giving informed consent
• People with any condition that would put them at unacceptable risk if they participated, or that would make it hard to interpret the study results
• People who have had major surgery within 28 days before joining the study, or who have not yet recovered from surgery
• Women who are pregnant or breastfeeding
• People who have recently received certain treatments, including chemotherapy, high-dose steroids, immunotherapy or antibody treatments, extensive radiation therapy, other experimental treatments, or any JAK inhibitor drug (including ruxolitinib), within specified timeframes before starting the study (confirm with trial site for exact timeframes)
• People who have recently taken certain medications that strongly affect how the body processes drugs (called strong CYP3A4 inhibitors or inducers), or fluconazole at doses above 200 mg daily, within a set period before starting the study
• People with a known allergy or sensitivity to drugs similar in makeup to thalidomide, lenalidomide, or steroids
• People currently receiving other cancer treatments
• People who have previously developed a specific type of skin reaction called erythema nodosum with a peeling rash while taking thalidomide or a similar drug
• People known to be HIV positive, or who have active or latent hepatitis B or C, or active or latent tuberculosis (TB)

Important: Always verify eligibility with the trial site directly before applying.